Bend Research and Xcelience have formed a collaboration to provide oral solid solubilization formulation solutions and clinical supply manufacture in combined programs to clients.

The collaboration aims to provide streamlined solutions to clients with challenging drug development candidates by combining Bend’s formulation/processing expertise for delivering poorly soluble compounds with Xcelience’s early-phase development expertise.

“This collaboration reduces project timelines and transfer risk more than would be possible if the two steps occurred sequentially,” said Xcelience chief executive officer and president Derek Hennecke. “It's a perfect example of what can happen when two organizations combine to push the boundaries of what it means to deliver great value.”

Rod Ray, chief executive officer of Bend Research, said, “We are combining Xcelience’s strengths in drug-product development and clinical-supply manufacturing with our company’s expertise in science- and engineering-based formulations for low-solubility compounds and our own drug-product intermediate clinical-supply manufacture. This will enable us to provide our high-quality, innovative solutions for clients in shorter timeframes, which can be critical in the development of new medicines.”